SCHEMBL6772816

SCHEMBL6772816

COC(=O)c1ccc(CS(=O)(=O)c2cccnc2)cc1-c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.43
MAPK1 P28482 1/20 0.43
USP2 O75604 1/20 0.42
USP8 P40818 1/20 0.42
NAMPT P43490 1/20 0.42
KMT2A Q03164 2/20 0.42
CFTR P13569 1/20 0.42
SLC2A1 P11166 1/20 0.42
HDAC7 Q8WUI4 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
MMP1 P03956 1/20 0.41
MMP9 P14780 1/20 0.41
MMP13 P45452 1/20 0.41
ADAM17 P78536 1/20 0.41
FGFR1 P11362 1/20 0.41
SRC P12931 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777428 0.80 KMT2A (0.49) MAPK1KMT2ACFTRSLC2A1HTT
SCHEMBL20178609 0.80 CFTR (0.52) MAPK1KMT2ACFTRSLC2A1GABRA1
SCHEMBL6773108 0.80 FNTA (0.54)
SCHEMBL6773111 0.80 FNTA (0.54)
SCHEMBL6777180 0.79 PDE4B (0.55) KMT2AHTT
SCHEMBL6778188 0.79 FNTA (0.54) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL3515844 0.79 NR4A2 (0.57) MAPK1KMT2ACFTRSLC2A1GABRA1
SCHEMBL6777063 0.78 PKM (0.46) MAPK1KMT2ACFTRSLC2A1
SCHEMBL6776674 0.78 FNTA (0.63)
SCHEMBL6776673 0.78 FNTA (0.63)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693123-B2 (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA UNIVERSITY OF PITTSBURGH 2004-02-17 US disclosed
EP-0873123-B1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 2003-04-09 EP disclosed
US-20020193596-A1 Inhibitors of protein isoprenyl transferases UNIVERSITY OF PITTSBURGH (US) 2002-12-19 US disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193596-A1 Inhibitors of protein isoprenyl transferases LANCL1, FNTB, DHCR7 PIK3CG 2424/4885MAPK1 3092/4885USP2 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.